Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $151.78 USD
Change Today -4.11 / -2.64%
Volume 4.4M
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

amgen inc (AMGN) Snapshot

Open
$155.33
Previous Close
$155.89
Day High
$156.35
Day Low
$151.30
52 Week High
07/31/15 - $181.81
52 Week Low
10/16/14 - $127.67
Market Cap
115.1B
Average Volume 10 Days
4.7M
EPS TTM
$8.25
Shares Outstanding
758.3M
EX-Date
08/13/15
P/E TM
18.4x
Dividend
$3.16
Dividend Yield
1.96%
Current Stock Chart for AMGEN INC (AMGN)

amgen inc (AMGN) Details

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company’s principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company’s other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.

17,900 Employees
Last Reported Date: 02/19/15
Founded in 1980

amgen inc (AMGN) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.4M
Executive Vice President of Operations
Total Annual Compensation: $943.0K
Executive Vice President of Global Commercial...
Total Annual Compensation: $1.0M
Executive Vice President of Research & Develo...
Total Annual Compensation: $899.9K
Compensation as of Fiscal Year 2014.

amgen inc (AMGN) Key Developments

Amgen Submits New Drug Application for Novel Intravenous Calcimimetic Etelcalcetide (AMG 416)

Amgen announced the submission of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) on hemodialysis. Etelcalcetide is a novel calcimimetic agent that suppresses the secretion of parathyroid hormone and is in clinical development for the treatment of SHPT in patients with CKD on hemodialysis. Etelcalcetide is administered intravenously three times per week at the end of each dialysis session. It acts by binding to and activating the calcium-sensing receptor on the parathyroid gland, thereby causing decreases in parathyroid hormone (PTH). Sustained elevations in PTH are known to be associated with significant clinical consequences for patients with CKD. The submission includes data from three Phase 3 studies, all of which met the primary endpoints, including two pooled placebo-controlled trials in more than 1,000 patients and a head-to-head study evaluating etelcalcetide compared with cinacalcet.

Amgen Inc. to Pay the State of Iowa $972,000 to Settle Allegations for Improper Marketing of Two of its Medications

Amgen Inc. will pay the State of Iowa more than $972,000 to settle allegations that it improperly marketed two of its medications. The settlement is part of a nationwide $72 million agreement with 48 states and the District of Columbia over allegations that the company unlawfully promoted anemia drug Aranesp and psoriasis drug Enbrel. The petition filed in Polk County District Court alleges that Amgen violated Iowa's consumer protection laws. The allegations include: Promoting Aranesp for dosing frequencies longer than the FDA approved label without competent and reliable scientific evidence to substantiate the extended dosing frequencies; Promoting Aranesp for anemia caused by cancer without having FDA approval or competent and reliable scientific evidence to support it; and Promoting Enbrel for mild plaque psoriasis even though Enbrel is only approved by the FDA to treat chronic moderate to severe plaque psoriasis. The agreement requires Amgen to reform its marketing practices and prevents it from promoting off-label uses of Enbrel and Aranesp. The company is barred from a variety of marketing strategies related to the two medications, including promoting off-label uses to medical professionals through non-profit drug reference books called compendia. In 2012 in New York, Amgen pleaded guilty to a federal charge that it illegally introduced misbranded drug Aranesp into the marketplace. Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of three drugs, including Aranesp.

Amgen to Pay $71 Million to Settle Investigation into Illegal Marketing of its Drugs Aranesp and Enbrel

Amgen announced that it will pay $71 million to settle an investigation into illegal marketing of its drugs Aranesp and Enbrel, ending an investigation by 48 states and Washington DC. The company was also accused of unauthorized promotion of Enbrel and its anti-infection drug Neulasta, and of offering kickbacks. The settlement agreement covered similar issues, including the dosing schedule of Aranesp, promotion of the drug as a treatment for anemia caused by cancer, and marketing of as a treatment for mild plaque psoriasis even though it's only approved for chronic moderate to severe plaque psoriasis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMGN:US $151.78 USD -4.11

AMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $62.41 USD -1.57
Allergan plc $303.74 USD -4.27
Eli Lilly & Co $82.35 USD -0.84
Medtronic PLC $72.29 USD -1.27
Novo Nordisk A/S kr369.20 DKK -0.30
View Industry Companies
 

Industry Analysis

AMGN

Industry Average

Valuation AMGN Industry Range
Price/Earnings 20.7x
Price/Sales 5.7x
Price/Book 4.3x
Price/Cash Flow 20.3x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit www.amgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.